Patents by Inventor Gillian Kingsbury

Gillian Kingsbury has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190359725
    Abstract: The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.
    Type: Application
    Filed: December 21, 2018
    Publication date: November 28, 2019
    Inventors: Lorenzo Benatuil, Maria A. Argiriadi, Bradford L. McRae, Chung-Ming Hsieh, David A. Egan, John E. Harlan, Russell A. Judge, Rui Wang, Gillian A. Kingsbury
  • Publication number: 20160319026
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: April 5, 2016
    Publication date: November 3, 2016
    Inventors: Tariq Ghayur, Junjian Liu, Gillian A. Kingsbury, Edward B. Reilly, Susan E. Morgan-Lappe, Jijie Gu
  • Patent number: 9029508
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: May 12, 2015
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
  • Publication number: 20150104452
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: June 10, 2014
    Publication date: April 16, 2015
    Inventors: Tariq Ghayur, Edward B. Reilly, Andrew Phillips, Randy L. Bell, Yingchun Li, Hua Ying, Susan E. Morgan-Lappe, Gillian A. Kingsbury, Jieyi Wang, Suzanne M. Norvell, Junjian Liu
  • Publication number: 20150017168
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: July 15, 2014
    Publication date: January 15, 2015
    Applicant: ABBVIE INC.
    Inventors: Tariq Ghayur, Junjian Liu, Gillian A. Kingsbury, Edward B. Reilly, Susan E. Morgan-Lappe
  • Patent number: 8444987
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders. In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: May 21, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Gillian A. Kingsbury, Kevin R. Leiby
  • Publication number: 20120270219
    Abstract: The invention provides isolated TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: July 2, 2012
    Publication date: October 25, 2012
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas A. Holtzman, John D. Sharp, Kevin R. Leiby, Steven Bossone, Yang Pan, Thomas M. Barnes, Christopher C. Fraser, Nicholas Wrighton, Paul S. Myers, Gillian Kingsbury
  • Publication number: 20120148573
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders. In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e.
    Type: Application
    Filed: May 26, 2011
    Publication date: June 14, 2012
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Gillian A. Kingsbury, Kevin R. Leiby
  • Patent number: 8163503
    Abstract: The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: April 24, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Gillian Kingsbury
  • Publication number: 20110263827
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: April 30, 2010
    Publication date: October 27, 2011
    Applicant: Abbott Laboratories
    Inventors: Tariq Ghayur, Junjian Liu, Gillian A. Kingsbury, Edward B. Reilly, Susan E. Morgan-lappe
  • Patent number: 7972797
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders. In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: July 5, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Gillian A. Kingsbury, Kevin R. Leiby
  • Publication number: 20110065124
    Abstract: The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 20, 2010
    Publication date: March 17, 2011
    Inventors: Douglas A. Holtzman, John D. Sharp, Kevin R. Leiby, Steven Bossone, Yang Pan, Thomas M. Barnes, Christopher C. Fraser, Nicholas Wrighton, Paul S. Myers, Gillian Kingsbury
  • Publication number: 20100260668
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: October 23, 2009
    Publication date: October 14, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Tariq Ghayur, Susan E. Morgan-lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying, Zhihong Liu
  • Publication number: 20100076178
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: April 28, 2009
    Publication date: March 25, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
  • Publication number: 20090304703
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders. In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e.
    Type: Application
    Filed: September 24, 2008
    Publication date: December 10, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Gillian A. Kingsbury, Kevin R. Leiby
  • Patent number: 7452980
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders. In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: November 18, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Gillian A. Kingsbury, Kevin R. Leiby
  • Publication number: 20080213778
    Abstract: The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: November 8, 2007
    Publication date: September 4, 2008
    Inventors: Douglas A. Holtzman, John D. Sharp, Kevin R. Leiby, Steven Bossone, Yang Pan, Thomas M. Barnes, Christopher C. Fraser, Nicholas Wrighton, Paul S. Myers, Gillian Kingsbury
  • Patent number: 7385036
    Abstract: The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: June 10, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Gillian Kingsbury
  • Publication number: 20070059303
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders. In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e.
    Type: Application
    Filed: November 14, 2006
    Publication date: March 15, 2007
    Inventors: Gillian Kingsbury, Kevin Leiby
  • Publication number: 20060216727
    Abstract: The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: November 23, 2005
    Publication date: September 28, 2006
    Inventors: Douglas Holtzman, John Sharp, Kevin Leiby, Steven Bossone, Yang Pan, Thomas Barnes, Christopher Fraser, Nicholas Wrighton, Paul Myers, Gillian Kingsbury